Interpace Biosciences
Interpace Biosciences is a life sciences company that provides molecular analysis and diagnostics to support cancer risk assessment, diagnosis, and treatment planning. Through its Interpace Diagnostics unit, it offers clinically beneficial molecular diagnostic tests and pathology services, including PancraGen, ThyGeNEXT, ThyraMIR, RespriDX and BarreGen, to help physicians evaluate indeterminate biopsies and guide patient management. The company develops and commercializes genomic tests and first-line assays that personalize medicine and improve diagnosis and treatment decisions. Its customers include physicians, hospitals, cancer centers, and clinics, reflecting a focus on esoteric molecular testing and related pathology services to aid cancer risk evaluation and therapeutic development.
2 past transactions
RedPath Integrated Pathology
Acquisition in 2014
RedPath Integrated Pathology, LLC is a reference laboratory based in Pittsburgh, Pennsylvania, specializing in oncology support services. Founded in 2004, the company operates a diagnostic platform known as PathFinderTG, which focuses on the early and definitive diagnosis of cancer. This platform utilizes advanced techniques to analyze genetic mutations, extracting objective and quantitative genetic information from small tissue biopsies, cytology samples, and fluid specimens. By providing these insights, RedPath aids pathologists, clinicians, and patients in resolving complex diagnostic challenges, particularly in cases where cancer treatments do not produce expected results.
Pharmakon
Acquisition in 2005
Pharmakon is a healthcare communications company focused on the marketing of ethical pharmaceutical and biotechnology products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.